Clinical efficacy and safety of venetoclax combined with multidrug chemotherapy in the treatment of 15 patients with relapsed or refractory early T-cell precursor acute lymphoblastic leukemia

• Published in: Zhōnghuá xuèyèxué zázhì Vol. 44; no. 8; p. 649
• Main Authors: Kong, J Y, Zong, L H, Pu, Y, Liu, Y, Kong, X, Li, M Y, Zhang, J, Song, B Q, Xue, S L, Tang, X W, Qiu, H Y, Wu, D P
• Format: Journal Article
• Language: Chinese
• Published: China 14-08-2023
• Subjects: Adult; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic - therapeutic use; Female; Humans; Leukemia, Myeloid, Acute - drug therapy; Male; Precursor Cells, T-Lymphoid; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy; Retrospective Studies; Treatment Outcome; Refractory; Leukemia, early T-cell precursor, acute; Combined chemotherapy; Relapsed; Venetoclax
• ISSN: 0253-2727
• DOI: 10.3760/cma.j.issn.0253-2727.2023.08.006

To explore the efficacy and safety of Venetoclax combined with multidrug chemotherapy in patients with relapsed or refractory early T-cell precursor acute lymphoblastic leukemia (R/R ETP-ALL) .
This study retrospectively analyzed 15 patients with R/R ETP-ALL who received Venetoclax combined with multidrug chemotherapy from December 2018 to February 2022. Among them, eight cases were combined with demethylated drugs, four cases were combined with demethylated drugs and HAAG chemotherapy regimen, two cases were combined with demethylated drugs and CAG regimen, and one case was combined with Cladribine. Specific usage and dosage of Venetoclax: 100 mg on day 1, 200 mg on day 2, 400 mg on day 3-28, orally; when combined with azole antifungal drugs, dosage was reduced to 100 mg/d.
Fifteen patients (10 males and 5 females) with R/R ETP-ALL were treated with Venetoclax and multidrug chemotherapy with a median age of 35 (12-42) years old. Of 4 refractory and 11 relapsed patients, the efficacy was evaluated on the 21th